Light-to-moderate alcohol consumption is linked to a reduced risk of heart attack, stroke and death among those with heart disease, according to a study published in the journal BMC Medicine on July 26.

Espero Pharmaceuticals – a commercial-stage cardiovascular pharma company – and Armetheon – a late-clinical stage pharma company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases – plan to merge.